Tectonic Therapeutic, Inc. (TECX): Total Assets
$261.04M
As of 2025-12-31
$237.03M
As of 2026-06-30
+35.9%
3-year compound annual growth
-0.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $261.04M | +70.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $152.91M | +288.1% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $39.40M | -62.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $103.95M | -49.0% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $203.84M | -24.8% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $271.23M | +35.3% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $200.51M | +50.2% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $133.48M | n/m | 2020-03-16, Balance as of period end |
| 2017-12-31 | $7.02M | n/a | 2019-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $261.04M | +70.7% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $258.34M | -42.4% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $268.69M | +82.9% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $245.96M | -13.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗